Marksans Pharma rises nearly 3% on UK health regulator approval for oral solution drug used in epilepsy treatment

In stock exchange filing, the company said that its wholly-owned subsidiary Relonchem Limited received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Levetiracetam Relonchem 100 mg/mL oral solution.

The oral solution is used for the treatment of certain seizures in epilepsy patients. The drug is used for the partial-onset, myoclonic, or tonic–clonic seizures. The company mentioned in the release that the product will be manufactured at the company’s UK manufacturing facility.

Earlier on April 18, the company informed the exchanges that a current Good Manufacturing Practices (cGMP) inspection was conducted at the company’s facility located in Verna, Goa, from April 9 to April 17. The company said that it has received five inspectional observations in Form 483 from the USFDA (United States Food and Drug Association).

The company informed the exchanges on May 13 that a meeting of the board of directors of the company will be held on May 30, to consider and approve the financial results for the quarter and year ended March 31, 2024. The company also said that the board will also consider the recommendation of a dividend if any for FY24.

Marksans Pharma shares closed at ₹165.8 apiece, up 0.6%, on the NSE.